. 2022 Mar 25;20(5):1056–1066. doi: 10.1111/jth.15689

TABLE 3.

E‐selectin inhibitors investigated for use in VTE and other disorders

Agent	Drug class	MOA	Preclinical model evaluated	Completed clinical trials	Ongoing clinical trials	FDA approval
GMI−1271 ⁹⁴ , ⁹⁵ , ⁹⁶ , ⁹⁷	Small molecule	E‐selectin antagonist	DVT, AML, MM, ALL, PDAC, CML, PC, HSCT	DVT, AML, MM	Phase 1: AML, MDS, MPAL Phase 1/2: AML, COVID−19 pneumonia Phase 2: Auto‐HCT for MM Phase 2/3: AML Phase 3: AML (see details below, Table 4)	Ongoing
GMI‐1687 ⁹⁸	Small molecule	E‐selectin antagonist	DVT, AML, VOC in SCD, CNV, MM			Pre‐clinical
GMI−1070 ⁹⁹	Small molecule	E‐selectin (primary) P‐, L‐selectin inhibitor (secondary)	VOC in SCD	SCD VOC		No

Agent

Drug class

MOA

Preclinical model evaluated

Completed clinical trials

Ongoing clinical trials

FDA approval

GMI−1271 ⁹⁴ , ⁹⁵ , ⁹⁶ , ⁹⁷

Small molecule

E‐selectin antagonist

DVT, AML, MM, ALL, PDAC, CML, PC, HSCT

DVT, AML, MM

Phase 1: AML, MDS, MPAL

Phase 1/2: AML, COVID−19 pneumonia

Phase 2: Auto‐HCT for MM

Phase 2/3: AML

Phase 3:

AML

(see details below, Table 4)

Ongoing

GMI‐1687 ⁹⁸

Small molecule

E‐selectin antagonist

DVT, AML, VOC in SCD, CNV, MM

Pre‐clinical

GMI−1070 ⁹⁹

Small molecule

E‐selectin (primary) P‐, L‐selectin inhibitor (secondary)

VOC in SCD

SCD VOC

Abbreviations: ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; CNV, corneal neovascularization; PC, prostate cancer; PDAC, pancreatic ductal adenocarcinoma.